

**Manuscript version: Author's Accepted Manuscript**

The version presented in WRAP is the author's accepted manuscript and may differ from the published version or Version of Record.

**Persistent WRAP URL:**

<http://wrap.warwick.ac.uk/161410>

**How to cite:**

The repository item page linked to above, will contain details on accessing citation guidance from the publisher.

**Copyright and reuse:**

The Warwick Research Archive Portal (WRAP) makes this work of researchers of the University of Warwick available open access under the following conditions.

This article is made available under the Creative Commons Attribution 4.0 International license (CC BY 4.0) and may be reused according to the conditions of the license. For more details see: <http://creativecommons.org/licenses/by/4.0/>.



**Publisher's statement:**

Please refer to the repository item page, publisher's statement section, for further information.

For more information, please contact the WRAP Team at: [wrap@warwick.ac.uk](mailto:wrap@warwick.ac.uk)

1 **Demographic patterns of human antibody levels to *Simulium damnosum* s.l.**  
2 **saliva in onchocerciasis-endemic areas: an indicator of exposure to vector**  
3 **bites**

4 Laura Willen<sup>1,2</sup> \*, Philip Milton<sup>3</sup>, Jonathan I.D. Hamley<sup>3</sup>, Martin Walker<sup>4</sup>, Mike Y. Osei-  
5 Atweneboana<sup>5</sup>, Petr Volf<sup>1</sup>, Maria-Gloria Basáñez<sup>3</sup>, Orin Courtenay<sup>6</sup> \*

6 <sup>1</sup> Department of Parasitology, Faculty of Science, Charles University, Prague, Czech Republic

7 <sup>2</sup> Centre for the Evaluation of Vaccinations, Vaccine and Infectious Disease Institute,  
8 University of Antwerp, Wilrijk, Belgium

9 <sup>3</sup> MRC Centre for Global Infectious Disease Analysis and London Centre for Neglected  
10 Tropical Disease Research, Department of Infectious Disease Epidemiology, School of Public  
11 Health, Imperial College London, London, UK

12 <sup>4</sup> London Centre for Neglected Tropical Disease Research and Department of Pathobiology  
13 and Population Sciences, Royal Veterinary College, Hatfield, UK

14 <sup>5</sup> Biomedical and Public Health Research Unit, CSIR-Water Research Institute, Accra, Ghana

15 <sup>6</sup> Zeeman Institute for Systems Biology & Infectious Disease Epidemiology Research and  
16 School of Life Sciences, University of Warwick, Coventry, UK

17

18 \* Corresponding author

19 E-mail: [laura.willen@gmail.com](mailto:laura.willen@gmail.com)

20 E-mail: [orin.courtenay@warwick.ac.uk](mailto:orin.courtenay@warwick.ac.uk)

21

## 22 **Abstract**

23 **Background:** In onchocerciasis endemic areas in Africa, heterogenous biting rates by  
24 blackfly vectors on humans are assumed to partially explain age- and sex-dependent infection  
25 patterns with *Onchocerca volvulus*. To underpin these assumptions and further improve  
26 predictions made by onchocerciasis transmission models, demographic patterns in antibody  
27 responses to salivary antigens of *Simulium damnosum* s.l. are evaluated as a measure of  
28 blackfly exposure.

29 **Methodology/Principal Findings:** Recently developed IgG and IgM anti-saliva  
30 immunoassays for *S. damnosum* s.l. were applied to blood samples collected from residents in  
31 four onchocerciasis endemic villages in Ghana. Demographic patterns in antibody levels  
32 according to village, sex and age were explored by fitting generalized linear models.  
33 Antibody levels varied between villages but showed consistent patterns with age and sex.  
34 Both IgG and IgM responses declined with increasing age. IgG responses were generally  
35 lower in males than in females and exhibited a steeper decline in adult males than in adult  
36 females. No sex-specific difference was observed in IgM responses.

37 **Conclusions/Significance:** The decline in age-specific antibody patterns suggested  
38 development of immunotolerance or desensitization to blackfly saliva antigen in response to  
39 persistent exposure. The variation between sexes, and between adults and youngsters may  
40 reflect differences in behaviour influencing cumulative exposure. These measures of antibody  
41 acquisition and decay could be incorporated into onchocerciasis transmission models towards  
42 informing onchocerciasis control, elimination, and surveillance.

## 43 **Author summary**

44 Onchocerciasis, a disease caused by the helminth parasite *Onchocerca volvulus*, is transmitted  
45 by the bites of female *Simulium* blackflies. The disease is still endemic in many African  
46 countries, and the World Health Organization has proposed elimination of its transmission in

47 12 countries by 2030. Understanding the heterogeneity in human exposure to vector bites can  
48 help discern which portion of the population is at higher risk of acquiring/ transmitting  
49 infection and is fundamental to identifying target groups for serological monitoring and  
50 transmission control. Traditionally, blackfly biting rates are estimated by performing human  
51 landing catches, a method that is often considered unethical and which can be unreliable as a  
52 representative measure. Therefore, we used our recently developed immunoassays to measure  
53 human antibody responses to antigens contained in the saliva of blackflies and deposited into  
54 human skin when they bloodfeed. In onchocerciasis endemic communities in Ghana, we  
55 measured antibody responses to understand age- and/or sex-related demographic patterns in  
56 vector exposure. We observed lower antibody responses in males compared to in females, and  
57 a substantial decline with increasing age, suggesting that high blackfly biting pressure induces  
58 desensitization in the human host.

## 59 **Introduction**

60 Female blackflies of the *Simulium damnosum* sensu lato (s.l.) complex are the predominant  
61 vectors of *Onchocerca volvulus* in Africa. This filarial nematode causes human  
62 onchocerciasis, commonly known as river blindness and proposed for elimination of  
63 transmission (EOT) in 12 countries by 2030 [1]. Repeat exposure to bites of infective  
64 blackflies is a key driver of parasite acquisition, and high biting rates are important  
65 determinants of transmission intensity and resurgence following control interventions,  
66 particularly those based on mass drug administration (MDA) of ivermectin [2,3]. Therefore,  
67 ‘stop-MDA surveys’ and post-treatment surveillance protocols would be improved by  
68 monitoring exposure to vector bites in addition to exposure to the parasite and assessment of  
69 residual infection in informative age and sex groups depending on the epidemiological setting  
70 [4,5]. Annual biting rates (ABR, the number of bites/person/year) are predominantly  
71 estimated by performing human landing catches (HLCs) [6], but this is both labour-intensive

72 and often considered unethical. Furthermore, HLC methods likely lead to biased estimates of  
73 ABRs as they are typically performed on a few adult males at the riverbank close to blackfly  
74 breeding sites, where biting rates are likely to be higher and vector collectors are maximally  
75 exposed [7]. Thus, HLCs may not capture the true exposure representative of the community,  
76 age or sex groups or their activity patterns. Furthermore, when blackfly densities are high,  
77 HLCs may be unable to capture all biting events thereby underestimating the biting rate [8,9].  
78 Applying novel methods to measure individual and population exposure to blackfly vector  
79 bites would greatly inform our understanding of exposure patterns to onchocerciasis and  
80 inform mathematical transmission modelling of control and elimination [2].

81 Proteins in the saliva of blood-seeking arthropod vectors of human and veterinary diseases  
82 provoke an immunomodulatory response in vertebrates following their exposure to vector  
83 bites (e.g. by mosquitoes, sand flies, triatomine bugs, and tsetse flies) [10]. Measurement of  
84 host anti-saliva antibodies has proven a useful surrogate marker to monitor individual host  
85 biting rates [11–15], seasonal variations in exposure and infection [16,17], and to evaluate  
86 vector control interventions [18–22]. Immunoassays to measure human anti-saliva antibody  
87 responses to blackfly bites have not been available until recently developed by the authors,  
88 specifically to measure human IgG and IgM antibody responses to saliva of *S. damnosum* s.l.  
89 which is the main vector in Africa including the study sites in Ghana [23].

90 In the present study we report on the demographic patterns revealed by applying these assays  
91 to community residents in the Bono East region of Ghana, a savannah setting. This area was  
92 under vector control during the Onchocerciasis Control Programme in West Africa (OCP,  
93 1974–2002) [24,25], and is where the first ivermectin community trials were conducted in the  
94 late 1980's [26]. However, transmission persists despite many years of annual MDA, even  
95 after adopting biannual MDA in 2010 [27,28]. With the risk of residual transmission leading  
96 to possible resurgence of human infections if MDA were to stop [3], the area has been the

97 subject of comprehensive entomological [27,29–31], parasitological [32] and parasite  
98 genomic [33] research, and a source of valuable epidemiological and entomological data for  
99 parameterizing onchocerciasis transmission models [34–36]. Due to the lack of reliable tools  
100 to independently measure human exposure to vector bites, mathematical models have  
101 assumed age- and sex-dependent exposure rates based on patterns of human infection with *O.*  
102 *volvulus*. However, modelling outputs used to inform EOT and surveillance strategies are  
103 sensitive to such patterns [4,37]. The aim of this study is to apply our novel human IgG and  
104 IgM immunoassays as indicators of individual biting exposure, both between and within (by  
105 age and sex) onchocerciasis-endemic communities. The generated demographic patterns will  
106 help to scrutinize mathematical modelling assumptions.

## 107 **Material and methods**

### 108 **Ethical statement**

109 Ethical clearance was obtained from the Council for Scientific and Industrial Research (CSIR)  
110 Institutional Review Board (RPN008/CSIR-IRB/2019) in Accra, Ghana. Residents were  
111 informed of the objectives of the study and participants provided fully informed written  
112 consent; parents or guardians provided consent for <18-year-olds. At the time of the study,  
113 ivermectin treatment against onchocerciasis was administered as part of the on-going national  
114 biannual MDA programme [38]. Each participant was rewarded with a bar of washing soap, a  
115 commercial sachet of malt drink powder (Milo, Nestlé) and a can of condensed milk. Blackfly  
116 collections were carried out by local OCP vector collectors following standard HLC  
117 techniques [39]. Individual identifiers on data records were anonymized prior to analyses and  
118 data storage.

### 119 **Study area**

120 The study was conducted during the wet season in August 2019 in rural villages in an  
121 onchocerciasis-endemic area of the Pru river basin, Pru District, in the Bono East region of

122 Ghana. Fig 1 provides a map of the study area and the location of the study communities,  
123 created using the ‘ggplot2’ and the ‘rworldmap’ package in R software [40,41].

124

125 **Fig 1. Map of Ghana indicating study communities in the Pru District, Bono East region.**

126

### 127 **Recruitment, blood sampling and demographic information**

128 Villages were selected on the criteria that (a) there was evidence of exposure to  
129 *S. damnosum* s.l. vector bites [30,42], (b) they were under current ivermectin treatment as part  
130 of the national onchocerciasis control programme [43], (c) the villages comprised >200  
131 residents, and (d) the villages represented variable ABRs based on previous records [30,42].  
132 Five villages were selected; due to the proximity of two of the villages, these were grouped  
133 into a single cluster (Asubende and Senyase (ASU/SEN) resulting in four village clusters.  
134 These included ASU/SEN, with high biting rates (400–850 flies/person/month), Beposo  
135 [BEP] with moderate values (100–350), and Fawoman [FAW] and Ohiampe [OHI] with  
136 lower biting rates (25–175 flies/person/month) [30,42].

137 To obtain blood samples from the village residents, two recruitment approaches were  
138 adopted: in villages with <300 residents (ASU/SEN, FAW, and OHI) all residents were  
139 invited to participate. In the larger village (BEP) an age/sex stratified sample was identified  
140 based on assigning random numbers generated using R software [44], to the pages of the  
141 paper-based census records compiled by the MDA programme. The households contained on  
142 randomly selected pages were noted and invited to participate until reaching an estimated  
143 sample of houses containing 250 individuals as required from statistical calculations (i.e.  
144 ~1000 individuals in total across the four village clusters). Children younger than 4 years old  
145 were not recruited.

146 A total of 958 participants were finally recruited, all tested for IgG antibodies, and a subset of  
 147 500 individuals tested for IgM antibodies (Table 1). For age stratification purposes, the  
 148 identified populations in all villages were divided into eight age categories (in years): 5–10,  
 149 11–20, 21–30, 31–40, 41–50, 51–60, 61–70, > 71, aiming to recruit 32 residents per age class  
 150 in each village, split equally between the sexes. In the case of IgM, samples were selected by  
 151 random number generation assigned to the ordered age-stratified full list of samples and  
 152 aimed to test around 40-60% of the samples tested by IgG per age class, with some variability  
 153 in percentage tested in the oldest age group. The numbers tested per age and sex strata per  
 154 village cluster are shown in Figs A and B and Table C in S1 File. The geographical  
 155 coordinates, elevation and number of individuals sampled and tested for each  
 156 immunoglobulin per village cluster are shown in Table 1.

157 **Table 1. Study communities, their geographical coordinates, elevation and numbers of**  
 158 **people sampled and tested for IgG and IgM per community in the Pru District, Ghana**

Community/ Cluster	Coordinates (degrees, minutes, seconds)		Elevation (masl)	No. sampled Tested for each immunoglobulin (%)	
	Long	Lat		IgG	IgM
<b>Asubende/ Senyase [ASU/SEN]</b>	08°01'08.8"N	00°58'52.4"W	153.3	186 100%	97 (52.2%)
<b>Beposo [BEP]</b>	08°00'26.7"N	000°57'40.2"W	118.0	253 100%	139 (54.9%)
<b>Fawoman [FAW]</b>	08°01'11.4"N	001°01'29.3"W	102.4	263 100%	124 (47.2%)
<b>Ohiampe [OHI]</b>	08°00'26.2"N	001°03'49.5"W	114.3	256 100%	140 (54.7%)
<b>Total</b>				958 100%	500 (52.2%)

159 Long: Longitude; Lat: Latitude; masl: metres above sea-level

160



161 Participants in each village/cluster were invited to the local school and assigned a  
162 subject/sample identification number written on a personalized card. Two to four ml of blood  
163 were collected into Ethylene Diamine Tetra Acetic acid (EDTA) tubes by venipuncture and  
164 kept cool for 2–3 hours in an insulated cool box until centrifugation at 2500 rpm for 15 min to  
165 separate the plasma. Samples were stored at 7° C until ELISA testing. Metadata on name, age,  
166 sex, number of years of residence, house number, name of household head, and history of  
167 clinical onchocerciasis were collected.

### 168 **Immunoassays to measure human exposure to blackfly bites**

169 Enzyme-linked immunosorbent assays (ELISA) previously developed were performed to  
170 measure anti-*S. damnosum* s.l. saliva IgG and IgM human responses [23]. Briefly, host-  
171 seeking *S. damnosum* s.l. females were collected following standard OCP vector collector  
172 techniques in one study location (ASU), near the Pru river [39]. All collected flies were stored  
173 in a cool box until dissected on the same day. The collected flies were anesthetized in a –20°  
174 C freezer for 10 min after which their salivary glands were removed, and aliquots stored in  
175 Tris-buffered saline (TBS) (one gland per  $\mu$ l TBS, pH 7.5) at –20° C until further use. Flat-  
176 bottom 96-well microtiter plates (ThermoFisher Scientific) were coated with blackfly salivary  
177 gland homogenate (SGH) with 0.2  $\mu$ g SGH/well (for IgG ELISA) or 0.025  $\mu$ g SGH/well (for  
178 IgM ELISA) and incubated overnight at 4° C. The plates were blocked with 6% non-fat dried  
179 milk (Bio-Rad) in phosphate-buffered saline (PBS) with 0.05% Tween 20 (PBS-Tw) and  
180 incubated with sera diluted 1/100 (IgG ELISA) or 1/50 (IgM ELISA) in 2% non-fat dried  
181 milk. The plates were washed and incubated with peroxidase-conjugated anti-human IgG  
182 (1/1,000) or IgM antibody (1/70,000) (Sigma-Aldrich; Bethyl Laboratories, Inc). The ELISA  
183 was developed using an orthophenyldiamine (OPD) solution in a phosphate-citrate buffer  
184 (pH 5.5) with 0.1% hydrogen peroxide. The reaction was stopped after 5 min with 10%  
185 sulfuric acid and the absorbance, optical density (OD) value was measured at 492 nm using a

186 Tecan Infinite M200 microplate reader (Schoeller). Further details of blackfly collection,  
187 dissection, and the immunoassays were previously reported [23].

### 188 **Data standardization**

189 All plasma samples were tested in duplicate. Samples with a coefficient of variation (CoV) of  
190 more than 20% were retested. Each plate included a blank control, the OD value of which was  
191 subtracted from the sample OD values. A set of two positive (PC) and two negative control  
192 (NC) samples were included in each plate to correct for inter-plate variability according to the  
193 following formula: Standardized Optical Density (SOD) =  $OD_{\text{sample}} / (\text{average } OD_{\text{PC}} - \text{average } OD_{\text{NC}})$ .  
194 Furthermore, a PC sample was titrated in duplicate on three separate plates at seven  
195 serial dilutions from 1/50 to 1/3,200. The average of the three log-logit transformed standard  
196 curves was used to convert and standardize sample SOD values which are reported below as  
197 anti-saliva antibody arbitrary units/ml.

### 198 **Sample size calculation**

199 Sample sizes were calculated to achieve 90% statistical power (with type I error,  $\alpha=0.05$ ) to  
200 detect a difference in mean IgG SOD antibody levels between males and females, for an  
201 unpaired two-sample effect size  $D_{\text{Cohen}}$  of 0.23 and a variance in SOD of 0.16 [45]. By adding  
202 15% to the calculated sample size as a correction factor for subsequent non-parametric  
203 statistical testing, 460 people per sex group were required [46]. This estimate is also based on  
204 the reasonable assumption that the differences in the mean antibody responses of the sexes  
205 between clusters would be minimal as confirmed by subsequent analyses (test of village  
206 cluster  $\times$  sex interaction term:  $P>0.243$ ). The equivalent statistical power to detect a  
207 difference in IgM responses between sexes with an effect size  $D_{\text{Cohen}}$  of 0.3 and a variance in  
208 SOD of 0.16 was 90%. Calculations were made in the R package ‘power’ using a two-sided t-  
209 test.

## 210 **Statistical analyses**

211 Differences between clusters or sex categories were statistically tested by Wilcoxon rank sum  
212 or Kruskal-Wallis tests with post-hoc Holm adjustment for multiple comparisons. Changes in  
213 immune responses with age and/or sex were tested by fitting generalized linear models  
214 (GLM) to the IgG and IgM anti-blackfly saliva antibody values, where a gamma distribution  
215 and log-link function gave the best fit by log-likelihood goodness-of-fit statistics. Age, sex  
216 and cluster interaction terms were tested, treating age as a continuous variable. Residence  
217 duration (years) and age showed high multicollinearity; hence only age was retained in the  
218 models. Correlation coefficients ( $r_s$ ) between median IgG and IgM responses by age and sex  
219 were estimated by the Spearman's rank method. All statistical analyses were performed in R  
220 software [44], and graphical representations created using the 'ggplot2' package in R [40].

## 221 **Results**

### 222 **Univariate analyses of population antibody response distributions**

223 A total of 958 participants (186–263 per village cluster) between the ages of  $\geq 5$  to  $< 96$  years  
224 old were recruited and sampled for anti-saliva IgG antibodies; demographic characteristics are  
225 summarized in Table 2 and in Figs A and B in S1 File. No differences were observed in the  
226 age compositions between village clusters or between sexes, nor in the frequencies of  
227 participants per age group (Figs A and B in S1 File). Thus, it is unlikely that the variations in  
228 age-sex compositions of village clusters were a source of statistical bias.

229 Univariate analyses of demographic variables detected significant differences between the  
230 median IgG responses among village clusters ( $P < 0.001$ ) (Fig 2A), and the median IgG  
231 responses of males and females ( $P < 0.05$ ) (Fig 2B). Equivalent differences were not observed  
232 in IgM responses (Fig 3); however, both IgG and IgM median antibody responses declined  
233 with age ( $P < 0.001$ ) (Fig 2D and 3D). A breakdown of the IgG and IgM antibody distribution  
234 with age per individual cluster is visualized in Figs D and E in S1 File.

235

236 **Fig 2. Human anti-blackfly saliva IgG antibody responses according to cluster, sex, and**  
237 **age.** Boxplots showing the distributions of IgG responses (A) by cluster, (B) by sex, (C) by  
238 age, and scatterplot (D) by age and sex (points) showing the best-fit lines (solid lines). IgG  
239 levels are shown as units/ml. F: female; M: male. Village clusters: ASU/SEN: Asubende/  
240 Senyase; BEP: Beposo; FAW: Fawoman; OHI: Ohiampe.

241

242 **Fig 3. Human anti-blackfly saliva IgM antibody responses according to cluster, sex and**  
243 **age.** Boxplots showing the distributions of IgM responses (A) by cluster, (B) by sex, (C) by  
244 age, and scatterplot (D) by age and sex (points) showing the best-fit lines (solid lines). IgM  
245 levels are shown as units/ml. F: female; M: male. Village clusters: ASU/SEN: Asubende/  
246 Senyase; BEP: Beposo; FAW: Fawoman; OHI: Ohiampe.

248 **Table 2. Summary statistics of participants and median antibody titres by immunoglobulin and village/cluster.**

Assay	Village	Participants (n)	Median age (Q1 – Q3) (in years)	Sex ratio (M:F)	Median duration of residency (Q1 – Q3) (in years)	Median antibody titre (units/ml)	Reported biting rate
<b>IgG</b>	<b>All</b>	958	21.0 (11.0 – 42.0)	0.84:1 (437:521)	16.0 (8.0 – 32.0)	2478.13 (1550.05 – 3413.36)	NA
	<b>ASU/SEN</b>	186	24.0 (14.0 – 39.0)	1:1 (93:93)	20.0 (10.0 – 35.0)	2507.34 (1699.94 – 3125.95)	High
	<b>BEP</b>	253	25.0 (11.0 – 46.0)	0.83:1 (115:138)	24.5 (11.0 – 46.0)	1951.63 (1269.37 – 2822.26)	Moderate
	<b>FAW</b>	263	22.0 (10.0 – 40.0)	0.71:1 (109:154)	13.0 (6.0 – 26.0)	2590.61 (1662.54 – 3535.01)	Low
	<b>OHI</b>	256	17.0 (11.0 – 40.5)	0.88:1 (120:136)	14.0 (7.0 – 24.0)	2956.20 (1703.47 – 4430.85)	Low
<b>IgM</b>	<b>All</b>	500	21.5 (10.0 – 42.0)	0.85:1 (230:270)	17.0 (7.0 – 35.0)	3628.43 (1687.59 – 9923.29)	NA
	<b>ASU/SEN</b>	97	23.0 (12.25 – 36.75)	1.37:1 (56:41)	21.0 (9.25 – 35.75)	2956.66 (1496.31 – 7690.82)	High
	<b>BEP</b>	137	24.0 (10.0 – 45.0)	0.72:1 (58:81)	24.0 (10.0 – 45.0)	4021.58 (1462.01 – 10396.13)	Moderate
	<b>FAW</b>	124	23.0 (9.0 – 40.0)	0.77:1 (54:70)	11.0 (6.0 – 29.0)	4102.16 (2148.38 – 10473.40)	Low
	<b>OHI</b>	140	17.5 (9.0 – 42.0)	0.79:1 (62:78)	15.0 (7.0 – 25.0)	3569.30 (1561.18 – 10754.69)	Low

250 The interquartile range (Q1 and Q3) of age, duration of residency, and the antibody titres are shown in brackets. Reported biting rates are

251 according to [30,42]. All: All clusters together; village clusters: ASU/SEN: Asubende/Senyase; BEP: Beposo; FAW: Fawoman; OHI: Ohiampe.

252 n: number; M: males; F: females; NA: not applicable

253 **Multivariate analyses of IgG responses according to village cluster, sex and age**

254 Accounting for cluster ID, sex, age, and the age x sex interaction term, multivariate models  
255 revealed that IgG responses were significantly lower in BEP than in ASU/SEN ( $P<0.01$ ),  
256 similar between ASU/SEN and FAW ( $P=0.406$ ), and higher in OHI than in ASU/SEN  
257 ( $P<0.001$ ) (Figs 4A and 5). Generally, males exhibited lower IgG responses than females  
258 ( $P<0.001$ ) (Figs 4B and 5). Fig 5 illustrates the (exponentiated) regression coefficient  
259 estimates of the final model (summarized in Table F in S1 File).

260

261 **Fig 4. Regression effect plots for all explanatory variables contained in the final model**  
262 **for the IgG responses.** Each plot visualizes the effect of a specific explanatory variable while  
263 fixing the others to their reference level. The panels show the variations in responses between  
264 village clusters (A), sex (B), age (C), and an interaction between age and sex (D). The vertical  
265 lines in panel A and B and the shaded regions around the lines in panel C and D represent the  
266 95% confidence intervals. M = Male; F = Female. Village clusters: ASU/SEN:  
267 Asubende/Senyase; BEP: Beposo; FAW: Fawoman; OHI: Ohiampe.

268

269 **Fig 5. Exponentiated regression coefficient estimates for the final model per assay.** The  
270 regression coefficient estimates for the final model are shown for IgG responses (A), and IgM  
271 responses (B). The circles represent the exponentiated mean coefficient estimate, the value  
272 shown above the corresponding circle, and the horizontal lines represent the 95% confidence  
273 intervals of the estimate. Significance levels \*\*\*  $P<0.001$ ; \*\*  $P<0.01$ ; \*  $P<0.05$ . The  
274 referents were Asubende/Senyase for village clusters, and females for both sex and the age x  
275 sex interaction term. Village clusters: BEP: Beposo; FAW: Fawoman, OHI: Ohiampe.

276

277 IgG anti-saliva antibody responses decreased with increasing age in both sexes ( $P < 0.001$ )  
278 (Figs 4C and 5), but the response in males declined at a faster rate than in females (test of age  
279  $\times$  sex interaction term;  $P < 0.001$ ) (Figs 4D and 5). Both adult male and female participants  
280  $\geq 18$  years old exhibited lower IgG antibody levels than those aged  $< 18$  years  
281 ( $P_{\text{females}} < 0.001$ ;  $P_{\text{males}} < 0.001$ ) (Fig 5). Males and females in pre-teenage years showed a  
282 similar antibody decline with increasing age (age  $\times$  sex interaction:  $P = 0.328$ ), whereas in  
283 adults the decline was more rapid in males than in females (age  $\times$  sex interaction:  $P < 0.01$ )  
284 (Fig 4D).

285

### 286 **Multivariate analyses of IgM responses according to village cluster, sex or age**

287 Equivalent multivariate analyses of anti-saliva IgM antibody responses for 500 recruits (Table  
288 1) indicated no significant variation between study clusters ( $P_{\text{BEP}} = 0.403$ ;  $P_{\text{FAW}} = 0.301$ ;  $P_{\text{OHI}}$   
289  $= 0.632$ ) or sex ( $P = 0.405$ ) (Figs 5 and 6A-B). However, there was a general decline in  
290 response magnitude with increasing age ( $P < 0.01$ ) (Figs 5 and 6C), but in contrast to IgG, the  
291 decline with age was not significantly different between sexes (test of age  $\times$  sex interaction  
292 term:  $P = 0.726$ ) (Fig 6D). Fig 5 illustrates the (exponentiated) regression coefficient estimates  
293 of the final model (summarized in Table F in S1 File).

294

### 295 **Fig 6. Regression effect plots for all explanatory variables contained in the final model**

296 **for the IgM responses.** Each plot visualizes the effect of a specific explanatory variable  
297 while fixing the others. The panels show the variations in responses between village clusters  
298 (A), sex (B), age (C), and an interaction between age and sex (D). The vertical lines in panel  
299 A and B and the shaded regions around the lines in panel C and D represent the 95%  
300 confidence intervals. M = Male; F = Female. Village clusters: ASU/SEN: Asubende/Senyase;  
301 BEP: Beposo; FAW: Fawoman; OHI: Ohiampe.

302

### 303 **Correlation between IgG and IgM responses**

304 The correlation between IgG and IgM antibody responses was generally low ( $r_s = 0.10$ ,  
305  $P < 0.05$ ), and not dissimilar considering females or males alone (females:  $r_s = 0.12$ ,  $P < 0.1$ ;  
306 males:  $r_s = 0.08$ ,  $P = 0.21$ ) (Fig F in S1 File).

307

### 308 **Discussion**

309 This study measured human antibody responses against blackfly saliva as an indicator of  
310 individual bite exposure; an approach that has been validated for several vector–host systems  
311 with the exception of blackflies [47,48]. Simuliids are important disease vectors of human and  
312 bovine onchocerciasis [49], mansonelliasis caused by *Mansonella ozzardi* [50], and vesicular  
313 stomatitis virus [51], yet they have not received as much attention as sand fly, mosquito or  
314 tick vectors. Only recently, we successfully developed novel immunoassays against blackfly  
315 saliva and this is the first study to apply these tools to an epidemiological setting. The  
316 appropriate use of these assays will also improve our understanding of *O. volvulus*  
317 transmission dynamics and will be used to monitor changes in biting rates and the success of  
318 vector control interventions [23]. Heterogenous exposure to blackfly bites is an important  
319 determinant of the observed age- and sex-dependent profiles of *O. volvulus* infection [5].  
320 Evaluating age- and sex-associated exposure patterns using empirically collected data can  
321 help inform transmission dynamics models, as these currently use assumed age- and sex-  
322 dependent exposure patterns that have, at best, been derived from fitting the models to age-  
323 and sex-specific infection profiles [5]. Such assumptions influence the choice of informative  
324 age groups for serological monitoring in stop-MDA surveys [4], and have implications for  
325 understanding the contribution of currently untreated groups to transmission and morbidity  
326 [37], as well as for the design and evaluation of potential prophylactic strategies [52]. Testing



327 such assumptions with independently collected data is crucial for better parameterization of  
328 transmission models and improved design of epidemiological surveys and surveillance  
329 strategies. Therefore, we explored age-and sex-related patterns of IgG and IgM antibody titres  
330 against *S. damnosum* s.l. saliva across well characterized endemic communities.

331 Both IgG and IgM antibody levels were high in children and gradually declined with  
332 increasing age. Similar trends have been observed in human antibody responses to the saliva  
333 of several mosquito species [53–58], posing the question of whether these patterns indicate  
334 decreasing exposure to vector bites with age, or increasing immune tolerance and  
335 desensitization with persistent or cumulative saliva exposure [59–62]. Investigation of human  
336 IgG responses to sand fly saliva supports the latter proposition, with higher anti-saliva  
337 antibody responses observed in new compared to long-term residents of a sand fly-endemic  
338 region [63]. Similarly, desensitization to salivary antigens was detected in an area colonized  
339 for more than 25 years by *Aedes* mosquitoes, compared to an area where individuals had been  
340 exposed for no longer than 5 years [54]. Following that pattern, median IgG antibody  
341 responses also tended to be lower in the current study villages where higher *S. damnosum* s.l.  
342 biting rates were previously reported [30,42]. Antibody responses to *Anopheles* mosquito  
343 bites measured after the summer season of high vector abundance were considerably higher  
344 than those before the summer season; notwithstanding they consistently declined with  
345 increasing host age [54,55]. Interestingly, in that study the decline appeared to be antigen-  
346 dependent, as the trend was not detected in antibody responses to a specific recombinantly-  
347 expressed protein as opposed to the whole salivary gland homogenate [64–66]. Several  
348 immunogenic proteins were recently detected in *S. damnosum* s.l. saliva of which most were  
349 well-known salivary antigens [23]. Future expression of these in recombinant forms may be  
350 instructive and increase assay sensitivity. This is especially interesting for IgM as these  
351 antibody responses were shown to be less specific than the IgG responses [23].

352 The median IgG response was lower in males than females, which can be attributed to the  
353 greater rate of decline of the IgG response with increasing age in males. This may reflect sex  
354 differences in behaviour such as daily habits, occupation, education, or clothing, that  
355 influence physical exposure to blood-seeking blackflies. Male occupants of most ages are  
356 responsible for agriculture, farming and fishing in the Pru region and may be less well  
357 covered by protective clothing, whereas women are more covered, spend more time at home  
358 performing domestic duties and/or engage in long-distance trading activities [67,68]. The  
359 current study was limited in not recording the daily activities of the participants, though biting  
360 blackflies appeared to be ubiquitous throughout the day within villages. That females show  
361 greater levels of non-specific innate and adaptive immune responsiveness than males,  
362 particularly post-puberty, suggests that hormonal involvement (reviewed in [69]) may  
363 contribute to the sex differences observed in this study.

364 A non-mutually exclusive alternative driving factor behind the observed decline in antibody  
365 levels may also be a lower exposure to blackfly bites with increasing age. Such patterns of  
366 exposure were predicted by fitting age- and sex-structured onchocerciasis transmission  
367 mathematical models to age- and sex-specific profiles of *O. volvulus* skin microfilariae in  
368 another African savannah setting [5]. However, the model fits also indicated that vector  
369 exposure of females should increase (rather than decrease) with age. If this is correct, and if  
370 women indeed are more intensely exposed as they age, it further supports the case for  
371 desensitization with increased long-term biting exposure. Therefore, one next step to better  
372 understand exposure patterns with age and sex is to fit dynamic models of antibody  
373 acquisition and decay to the (IgG) data obtained here [70,71]. Future studies of the molecular  
374 and cellular mechanisms that underly immune tolerance and progressive desensitization to  
375 blackfly saliva would also be most informative. Variations in IgG subclass responsiveness are

376 also possible as shown against *Anopheles* or *Aedes* saliva [55,72]. Interestingly, human IgG4  
377 amongst bee-keepers was found to be associated with immunotolerance to bee venom [73,74].

378 Less clear in this study were the age and sex-related trends in IgM responses.  
379 Although they also declined with age supporting the immunological desensitization  
380 hypothesis, IgM responses are generally shorter lived than IgG responses, hence, likely to be  
381 more indicative of recent exposure. A shorter half-life together with a lack of cumulative  
382 increase after repeat exposure may partially explain the large number of low IgM responses  
383 observed in the village residents, and the lack of correlations between individual host IgG and  
384 IgM responses, particularly as the current study was limited to cross-sectional sampling  
385 during the high biting season.

386 Future studies would benefit from quantifying short- and long-term kinetics in  
387 individual anti-saliva Ig responses in the context of seasonal fluctuations in vector abundance  
388 and distance to vector breeding habitats, to refine our understanding of the link between biting  
389 rates and the Ig responses [16,53,54]. In fact, it would be very informative if antibody data  
390 generated using our immunoassays could be used in spatial analyses to better understand  
391 patterns of vector–human contact with increasing distance from breeding sites. At present,  
392 mapping exercises such as those used for Onchocerciasis Elimination Mapping (OEM) collect  
393 information on the distribution of breeding sites and vector presence. Our novel tool could  
394 complement OEM to identify high-risk locations where exposure to vector bites would  
395 provide additional information to seroprevalence surveys to guide start-MDA decisions and  
396 identify informative age/sex groups for sampling [75]. Most of the information about the  
397 relationship between vector density and distance from breeding sites pertains to African  
398 savannah settings (such as those explored here), with less data available to characterize such a  
399 relationship in forest and forest-savannah mosaic settings. Therefore, if our anti-vector saliva  
400 assays could be combined with (seroprevalence) parasite exposure assays for a range of

401 epidemiological settings, it would be possible to obtain valuable information to help  
402 elimination efforts. However, this necessitates the testing and validation of our assays for  
403 other species/cytoforms of the *S. damnosum* complex.

404         The predominant vector species in the Bono East region are the savannah members of  
405 the complex, *S. damnosum sensu stricto/S. sirbanum* [27,30]. It remains to be established if  
406 the anti-*S. damnosum* s.l. IgG and IgM antibody responses represent a *damnosum* complex-  
407 specific marker, or if member-specific markers of exposure would be more sensitive. We  
408 acknowledge that more data need to be collected to ascertain the validity of our  
409 immunoassays to reliably measure exposure to vector bites. Regarding empirical approaches,  
410 there are no experimental or observational data yet to precisely quantify the relationship  
411 between anti-salivary antibody levels and the number of vector bites. As colonizing blackflies  
412 in the laboratory is notoriously difficult, collecting field data to understand the kinetics of the  
413 antibody responses over a specified time frame would be helpful, particularly in settings with  
414 strong seasonality, in which vector biting ceases or greatly decreases for several months  
415 during the year. Regarding theoretical approaches, and as mentioned earlier, the exposure  
416 profiles predicted by age- and sex-structured onchocerciasis transmission models are broadly  
417 consistent with the proposed desensitization hypothesis. If this proves to be the case, we  
418 expect vector saliva-naïve children still to respond well to salivary antigens as an indication of  
419 continued exposure to vector bites pre- or post-MDA campaigns in areas with no vector  
420 control or without major ecological changes affecting vector density. Our assay could then be  
421 used to understand potential secular trends in vector biting rates due to anthropogenic change.  
422 Ideally, multiplex assays could be developed to test simultaneously for both exposure to  
423 vector bites and to parasite antigens.

424 **Conclusion**

425 Serological anti-saliva assays are useful tools to complement information collected by HLCs  
426 by measuring human-vector contact and revealing heterogeneities in exposure at the  
427 individual and community level that cannot be unravelled by HLCs alone. By novel  
428 application to four onchocerciasis-endemic communities, this study successfully evaluated  
429 age- and sex-related demographic patterns in blackfly bite exposure. The analyses uncovered  
430 the possibility of age- and sex-specific immunotolerance or desensitization to blackfly saliva,  
431 likely resulting from cumulative blackfly exposure with age. Concomitant studies of infection  
432 levels in humans and flies, vector abundance, and immune responses to blackfly saliva and  
433 parasite antigens would greatly help to better understand transmission risk and intensity, and  
434 improve parameterization of transmission models with which to inform optimal interventions  
435 and surveillance strategies to achieve and protect onchocerciasis elimination.

436

437 **Acknowledgements**

438 Special thanks go to Dr. Francis Veriegh, Frank Aboagye-Twum and Bright Idun for assisting  
439 in the blood sampling and the collection of blackfly salivary glands. We gratefully  
440 acknowledge the researchers at the Noguchi Memorial Institute for Medical Research in  
441 Accra for allowing us access to their laboratory facilities. We also thank all the participants of  
442 the study, who were crucial to the execution of the study.

443

444

445 **References**

- 446 1. World Health Organization. Department of Control of Neglected Tropical Diseases.  
447 Ending the neglect to attain the Sustainable Development Goals – A road map for  
448 neglected tropical diseases 2021–2030. Geneva World Health Organization. 2021  
449 (Editor: Malecele MN). Available:  
450 <https://www.who.int/publications/i/item/9789240010352> (accessed 11 December  
451 2021).
- 452 2. Hamley JID, Milton P, Walker M, Basáñez MG. Modelling exposure heterogeneity and  
453 density dependence in onchocerciasis using a novel individual-based transmission  
454 model, EPIONCHO-IBM: Implications for elimination and data needs. *PLoS Negl*  
455 *Trop Dis.* 2019;13: 1–21. doi:10.1371/journal.pntd.0007557
- 456 3. Walker M, Stolk WA, Dixon MA, Bottomley C, Diawara L, Traoré MO, et al.  
457 Modelling the elimination of river blindness using long-term epidemiological and  
458 programmatic data from Mali and Senegal. *Epidemics.* 2017;18: 4–15.  
459 doi:10.1016/j.epidem.2017.02.005
- 460 4. Hamley JID, Walker M, Coffeng LE, Milton P, de Vlas SJ, Stolk WA, et al. Structural  
461 uncertainty in onchocerciasis transmission models influences the estimation of  
462 elimination thresholds and selection of age groups for seromonitoring. *J Infect Dis.*  
463 2020;221: S510–S518. doi:10.1093/infdis/jiz674
- 464 5. Filipe JAN, Boussinesq M, Renz A, Collins RC, Vivas-Martinez S, Grillet ME, et al.  
465 Human infection patterns and heterogeneous exposure in river blindness. *Proc Natl*  
466 *Acad Sci USA.* 2005;102: 15265–15270. doi:10.1073/pnas.0502659102
- 467 6. Otabil KB, Gyasi SF, Awuah E, Obeng-Ofori D, Rodríguez-Pérez MA, Katholi CR, et  
468 al. The search for an efficient black fly trap for xenomonitoring of onchocerciasis. *J*  
469 *Parasitol Res.* 2018;2018: 1–10. doi:10.1155/2018/5902367
- 470 7. Renz A, Wenk P. Studies on the dynamics of transmission of onchocerciasis in a  
471 Sudan-savanna area of North Cameroon IV. The different exposure to *Simulium* bites  
472 and transmission of boys and girls and men and women, and the resulting  
473 manifestations of onchocerciasis. *Ann Trop Med Parasitol.* 1987;81: 215–228.  
474 doi:10.1080/00034983.1987.11812115
- 475 8. Talom BAD, Enyong P, Cheke RA, Djouaka R, Hawkes FM. Capture of high numbers  
476 of *Simulium* vectors can be achieved with Host Decoy Traps to support data acquisition  
477 in the onchocerciasis elimination endgame. *Acta Trop.* 2021;221: 106020.  
478 doi:10.1016/j.actatropica.2021.106020
- 479 9. Jacobi CA, Enyong P, Renz A. Individual exposure to *Simulium* bites and intensity of  
480 *Onchocerca volvulus* infection. *Parasit Vectors.* 2010;3: 1–6.
- 481 10. Arcà B, Ribeiro JM. Saliva of hematophagous insects: a multifaceted toolkit. *Curr*

- 482 Opin Insect Sci. 2018;29: 102–109. doi:10.1016/j.cois.2018.07.012
- 483 11. Fontaine A, Pascual A, Orlandi-Pradines E, Diouf I, Remoué F, Pagès F, et al.  
484 Relationship between exposure to vector bites and antibody responses to mosquito  
485 salivary gland extracts. PLoS One. 2011;6: e29107. doi:10.1371/journal.pone.0029107
- 486 12. Doucoure S, Mouchet F, Cornélie S, DeHecq JS, Rutee AH, Roca Y, et al. Evaluation  
487 of the human IgG antibody response to *Aedes albopictus* saliva as a new specific  
488 biomarker of exposure to vector bites. PLoS Negl Trop Dis. 2012;6: e1487.  
489 doi:10.1371/journal.pntd.0001487
- 490 13. Vlkova M, Rohousova I, Hostomska J, Pohankova L, Zidkova L, Drahota J, et al.  
491 Kinetics of antibody response in BALB/c and C57BL/6 mice bitten by *Phlebotomus*  
492 *papatasi*. PLoS Negl Trop Dis. 2012;6: e1719. doi:10.1371/journal.pntd.0001719
- 493 14. Caljon G, Van Den Abbeele J, Sternberg JM, Coosemans M, De Baetselier P, Magez S.  
494 Tsetse fly saliva biases the immune response to Th2 and induces anti-vector antibodies  
495 that are a useful tool for exposure assessment. Int J Parasitol. 2006;36: 1025–1035.  
496 doi:10.1016/j.ijpara.2006.05.002
- 497 15. Schwarz A, Sternberg JM, Johnston V, Medrano-Mercado N, Anderson JM, Hume  
498 JCC, et al. Antibody responses of domestic animals to salivary antigens of *Triatoma*  
499 *infestans* as biomarkers for low-level infestation of triatomines. Int J Parasitol.  
500 2009;39: 1021–1029. doi:10.1016/j.ijpara.2009.01.010
- 501 16. Kostalova T, Lestinova T, Sumova P, Vlkova M, Rohousova I, Berriatua E, et al.  
502 Canine antibodies against salivary recombinant proteins of *Phlebotomus perniciosus*: A  
503 longitudinal study in an endemic focus of canine leishmaniasis. PLoS Negl Trop Dis.  
504 2015;9: e0003855. doi:10.1371/journal.pntd.0003855
- 505 17. Quinnell RJ, Soremekun S, Bates PA, Rogers ME, Garcez LM, Courtenay O. Antibody  
506 response to sand fly saliva is a marker of transmission intensity but not disease  
507 progression in dogs naturally infected with *Leishmania infantum*. Parasit Vectors.  
508 2018;11: 1–12. doi:10.1186/s13071-017-2587-5
- 509 18. Brosseau L, Drame PM, Besnard P, Toto JC, Foumane V, Le Mire J, et al. Human  
510 antibody response to *Anopheles* Saliva for comparing the efficacy of three malaria  
511 vector control methods in Balombo, Angola. PLoS One. 2012;7: e44189.  
512 doi:10.1371/journal.pone.0044189
- 513 19. Drame PM, Poinignon A, Besnard P, Le Mire J, Dos-Santos MA, Sow CS, et al.  
514 Human antibody response to *Anopheles gambiae* saliva: An immuno-epidemiological  
515 biomarker to evaluate the efficacy of insecticide-treated nets in malaria vector control.  
516 Am J Trop Med Hyg. 2010;83: 115–121. doi:10.4269/ajtmh.2010.09-0684
- 517 20. Gidwani K, Picado A, Rijal S, Singh SP, Roy L, Volfova V, et al. Serological markers  
518 of sand fly exposure to evaluate insecticidal nets against visceral leishmaniasis in India  
519 and Nepal: A cluster-randomized trial. PLoS Negl Trop Dis. 2011;5: e1296.

- 520 doi:10.1371/journal.pntd.0001296
- 521 21. Dinesh DS, Das P, Picado A, Davies C, Speybroeck N, Ostyn B, et al. Long-lasting  
522 insecticidal nets fail at household level to reduce abundance of sandfly vector  
523 *Phlebotomus argentipes* in treated houses in Bihar (India). *Trop Med Int Health*.  
524 2008;13: 953–958. doi:10.1111/j.1365-3156.2008.02096.x
- 525 22. Schwarz A, Juarez JA, Richards J, Rath B, Machaca VQ, Castro YE, et al. Anti-  
526 triatomine saliva immunoassays for the evaluation of impregnated netting trials against  
527 Chagas disease transmission. *Int J Parasitol*. 2011;41: 591–594.  
528 doi:10.1016/j.ijpara.2011.02.001
- 529 23. Willen L, Basáñez MG, Dvorak V, Veriegh FBD, Aboagye FT, Idun B, et al. Human  
530 immune response against salivary antigens of *Simulium damnosum* s.l.: A new  
531 epidemiological marker for exposure to blackfly bites in onchocerciasis endemic areas.  
532 *PLoS Negl Trop Dis*. 2021;15: e0009512. doi:10.1371/journal.pntd.0009512
- 533 24. Hougard J-M, Alley ES, Yaméogo L, Dadzie KY, Boatn BA. Eliminating  
534 onchocerciasis after 14 years of vector control: A proved strategy. *J Infect Dis*.  
535 2001;184: 497–503. doi:10.4000/books.irdeditions.29100
- 536 25. O’Hanlon SJ, Slater HC, Cheke RA, Boatn BA, Coffeng LE, Pion SDS, et al. Model-  
537 based geostatistical mapping of the prevalence of *Onchocerca volvulus* in West Africa.  
538 *PLoS Negl Trop Dis*. 2016;10: e0004328. doi:10.1371/journal.pntd.0004328
- 539 26. Alley ES, Plaisier AP, Boatn BA, Dadzie KY, Remme J, Zerbo G, et al. The impact of  
540 five years of annual ivermectin treatment on skin microfilarial loads in the  
541 onchocerciasis focus of Asubende, Ghana. *Trans R Soc Trop Med Hyg*. 1994;88: 581–  
542 584. doi:10.1016/0035-9203(94)90172-4
- 543 27. Lamberton PHL, Cheke RA, Winskill P, Tirados I, Walker M, Osei-Atweneboana MY,  
544 et al. Onchocerciasis transmission in Ghana: Persistence under different control  
545 strategies and the role of the simuliid vectors. *PLoS Negl Trop Dis*. 2015;9: e0003688.  
546 doi:10.1371/journal.pntd.0003688
- 547 28. Osei-Atweneboana MY, Eng JKL, Boakye DA, Gyapong JO, Prichard RK. Prevalence  
548 and intensity of *Onchocerca volvulus* infection and efficacy of ivermectin in endemic  
549 communities in Ghana: a two-phase epidemiological study. *Lancet*. 2007;369: 2021–  
550 2029. doi: 10.1016/S0140-6736(07)60942-8. .
- 551 29. Post RJ, Cheke RA, Boakye DA, Wilson MD, Osei-Atweneboana MY, Tetteh-Kumah  
552 A, et al. Stability and change in the distribution of cytospecies of the *Simulium*  
553 *damnosum* complex (Diptera: Simuliidae) in southern Ghana from 1971 to 2011.  
554 *Parasit Vectors*. 2013;6: 1–11. doi:10.1186/1756-3305-6-205
- 555 30. Lamberton PHL, Cheke RA, Walker M, Winskill P, Osei-Atweneboana MY, Tirados I,  
556 et al. Onchocerciasis transmission in Ghana: Biting and parous rates of host-seeking  
557 sibling species of the *Simulium damnosum* complex. *Parasit Vectors*. 2014;7: 511.



- 558 doi:10.1186/s13071-014-0511-9
- 559 31. Cheke RA, Basáñez M, Perry M, White M, Garms R, Obuobie E, et al. Potential effects  
560 of warmer worms and vectors on onchocerciasis transmission in West Africa. *Philos*  
561 *Trans R Soc B Biol Sci.* 2015;370: 20130559. doi: 10.1098/rstb.2013.0559.
- 562 32. Frempong KK, Walker M, Cheke RA, Teteve EJ, Gyan ET, Owusu EO, et al. Does  
563 increasing treatment frequency address suboptimal responses to ivermectin for the  
564 control and elimination of river blindness? *Clin Infect Dis.* 2016;62: 1338–1347.  
565 doi:10.1093/cid/ciw144
- 566 33. Doyle SR, Bourguinat C, Nana-Djeunga HC, Kengne-Ouafo JA, Pion SDS, Bopda J, et  
567 al. Genome-wide analysis of ivermectin response by *Onchocerca volvulus* reveals that  
568 genetic drift and soft selective sweeps contribute to loss of drug sensitivity. *PLoS Negl*  
569 *Trop Dis.* 2017;11: e0005816. doi:10.1371/journal.pntd.0005816
- 570 34. Plaisier AP, van Oortmarsen GJ, Habbema JDF, Remme J, Alley ES. ONCHOSIM: a  
571 model and computer simulation program for the transmission and control of  
572 onchocerciasis. *Comput Methods Programs Biomed.* 1990;31: 43–56.  
573 doi:10.1016/0169-2607(90)90030-d.
- 574 35. Basáñez MG, Churcher TS, Grillet ME. *Onchocerca-Simulium* interactions and the  
575 population and evolutionary biology of *Onchocerca volvulus*. *Adv Parasitol.* 2009;68:  
576 263–313. doi:10.1016/S0065-308X(08)00611-8
- 577 36. Basáñez MG, Walker M, Turner HC, Coffeng LE, de Vlas SJ, Stolk WA. River  
578 blindness: Mathematical models for control and elimination. *Adv Parasitol.* 2016;94:  
579 247–341. doi:10.1016/bs.apar.2016.08.003
- 580 37. Hamley JID, Blok DJ, Walker M, Milton P, Hopkins AD, Hamill LC, et al. What does  
581 the COVID-19 pandemic mean for the next decade of onchocerciasis control and  
582 elimination? *Trans R Soc Trop Med Hyg.* 2021;115: 269–280.  
583 doi:10.1093/trstmh/traa193
- 584 38. Turner HC, Osei-Atweneboana MY, Walker M, Tetteve EJ, Churcher TS, Asiedu O, et  
585 al. The cost of annual versus biannual community-directed treatment of onchocerciasis  
586 with ivermectin: Ghana as a case study. *PLoS Negl Trop Dis.* 2013;7: e2452.  
587 doi:10.1371/journal.pntd.0002452
- 588 39. Walsh JF, Davies JB, Le Berre R, Garms R. Standardization of criteria for assessing  
589 the effect of *Simulium* control in onchocerciasis control programmes. *Trans R Soc Trop*  
590 *Med Hyg.* 1978;72: 675–676. doi:10.1016/0035-9203(78)90039-1
- 591 40. Wickham H. *ggplot2: Elegant Graphics for Data Analysis.* Springer-Verlag New York,  
592 2009.
- 593 41. South A. *rworldmap: A New R package for Mapping Global Data.* *R J.* 2011;3: 35–43.
- 594 42. Veriegh FBD. Impacts of semi-annual ivermectin treatment and the spatio-temporal

- 595 distribution and abundance of *Simulium damnosum* sensu lato vectors on the  
596 transmission of *Onchocerca volvulus*. PhD Thesis. Kwame Nkrumah University of  
597 Science and Technology (KNUST), Ghana. 2020.
- 598 43. Biritwum NK, de Souza DK, Asiedu O, Marfo B, Amazigo UV, Gyapong JO.  
599 Onchocerciasis control in Ghana (1974–2016). *Parasit Vectors*. 2021;14: 1–9.  
600 doi:10.1186/s13071-020-04507-2
- 601 44. R Core Team (2015). R: A language and environment for statistical computing. R  
602 Foundation for Statistical Computing, Vienna, Austria. Available: [https://www.r-](https://www.r-project.org/)  
603 [project.org/](https://www.r-project.org/) (accessed 11 December 2021).
- 604 45. Cohen J. *Statistical Power Analysis for the Behavioral Sciences*. Second edition.  
605 Lawrence Erlbaum Associates; 1988.
- 606 46. Ryan TP. *Sample Size Determination and Power*. John Wiley & Sons, Inc.; 2013.  
607 doi:10.1002/9781118439241
- 608 47. Andrade BB, Teixeira CR. Biomarkers for exposure to sand flies bites as tools to aid  
609 control of leishmaniasis. *Front Immunol*. 2012;3: 121. doi:10.3389/fimmu.2012.00121
- 610 48. Lestnova T, Rohousova I, Sima M, de Oliveira CI, Volf P. Insights into the sand fly  
611 saliva: Blood-feeding and immune interactions between sand flies, hosts, and  
612 *Leishmania*. *PLoS Negl Trop Dis*. 2017;11: e0005600.  
613 doi:10.1371/journal.pntd.0005600
- 614 49. Doyle SR, Armoo S, Renz A, Taylor MJ, Osei-Atweneboana MY, Grant WN.  
615 Discrimination between *Onchocerca volvulus* and *O. ochengi* filarial larvae in  
616 *Simulium damnosum* (s.l.) and their distribution throughout central Ghana using a  
617 versatile high-resolution speciation assay. *Parasit Vectors*. 2016;9: 536.  
618 doi:10.1186/s13071-016-1832-7
- 619 50. Yarzabal L, Basáñez MG, Ramírez-Pérez J, Ramírez A, Botto C, et al. Experimental  
620 and natural infection of *Simulium sanchezii* by *Mansonella ozzardi* in the Middle  
621 Orinoco region of Venezuela. *Trans R Soc Trop Med Hyg*. 1985;79: 29–33.  
622 doi:10.1016/0035-9203(85)90226-3
- 623 51. Cupp EW, Maré CJ, Cupp MS, Ramberg FB. Biological transmission of vesicular  
624 stomatitis virus (New Jersey) by *Simulium vittatum* (Diptera: Simuliidae). *J Med*  
625 *Entomol*. 1992;29: 137–140. doi:10.1093/jmedent/29.2.137
- 626 52. Turner HC, Walker M, Lustigman S, Taylor DW, Basáñez MG. Human  
627 onchocerciasis: Modelling the potential long-term consequences of a vaccination  
628 programme. *PLoS Negl Trop Dis*. 2015;9: e0003938.  
629 doi:10.1371/journal.pntd.0003938
- 630 53. Rizzo C, Ronca R, Fiorentino G, Verra F, Mangano V, Poinsignon A, et al. Humoral  
631 response to the *Anopheles gambiae* salivary protein gSG6: A serological indicator of

- 632 exposure to Afrotropical malaria vectors. PLoS One. 2011;6: e17980.  
633 doi:10.1371/journal.pone.0017980
- 634 54. Buezo Montero S, Gabrieli P, Montarsi F, Borean A, Capelli S, De Silvestro G, et al.  
635 IgG antibody responses to the *Aedes albopictus* 34k2 salivary protein as novel  
636 candidate marker of human exposure to the tiger mosquito. Front Cell Infect Microbiol.  
637 2020;10: 377. doi:10.3389/fcimb.2020.00377
- 638 55. Rizzo C, Ronca R, Lombardo F, Mangano V, Sirima SB, Nèbiè I, et al. IgG1 and IgG4  
639 antibody responses to the *Anopheles gambiae* salivary protein gSG6 in the sympatric  
640 ethnic groups Mossi and Fulani in a malaria hyperendemic area of Burkina Faso. PLoS  
641 One. 2014;9: e96130. doi:10.1371/journal.pone.0096130
- 642 56. Londono-Renteria B, Drame PM, Montiel J, Vasquez AM, Tobón-Castaño A, Taylor  
643 M, et al. Identification and pilot evaluation of salivary peptides from *Anopheles*  
644 *albimanus* as biomarkers for bite exposure and malaria infection in Colombia. Int J  
645 Mol Sci. 2020;21: 691. doi:10.3390/ijms21030691
- 646 57. Montiel J, Carbal LF, Tobón-Castaño A, Vásquez GM, Fisher ML, Londono-Rentería  
647 B. IgG antibody response against *Anopheles* salivary gland proteins in asymptomatic  
648 *Plasmodium* infections in Nariño, Colombia. Malar J. 2020;19: 42.  
649 doi:10.1186/s12936-020-3128-9
- 650 58. Poinsignon A, Cornélie S, Ba F, Boulanger D, Sow C, Rossignol M, et al. Human IgG  
651 response to a salivary peptide, gSG6-P1, as a new immuno-epidemiological tool for  
652 evaluating low-level exposure to *Anopheles* bites. Malar J. 2009;8: 198.  
653 doi:10.1186/1475-2875-8-198
- 654 59. Peng Z, Simons FER. Mosquito allergy: Immune mechanisms and recombinant  
655 salivary allergens. Int Arch Allergy Immunol. 2004;133: 198–209.  
656 doi:10.1159/000076787
- 657 60. Feingold BF, Benjamini E, Michaeli D. The allergic responses to insect bites. Annu  
658 Rev Entomol. 1968;13: 137–158. doi:10.1146/annurev.en.13.010168.001033
- 659 61. Peng Z, Simons FER. A prospective study of naturally acquired sensitization and  
660 subsequent desensitization to mosquito bites and concurrent antibody responses. J  
661 Allergy Clin Immunol. 1998;101: 284–286. doi:10.1016/S0091-6749(98)70395-1
- 662 62. Mellanby K. Man's reaction to mosquito bites. Nature. 1946;158: 554.
- 663 63. Mondragon-Shem K, Al-Salem WS, Kelly-Hope L, Abdeladhim M, Al-Zahrani MH,  
664 Valenzuela JG, et al. Severity of Old World cutaneous leishmaniasis is influenced by  
665 previous exposure to sandfly bites in Saudi Arabia. PLoS Negl Trop Dis. 2015;9:  
666 e0003449. doi:10.1371/journal.pntd.0003449
- 667 64. Rizzo C, Lombardo F, Ronca R, Mangano V, Sirima S, Nèbiè I, et al. Differential  
668 antibody response to the *Anopheles gambiae* gSG6 and cE5 salivary proteins in

- 669 individuals naturally exposed to bites of malaria vectors. *Parasit Vectors*. 2014;7: 549.  
670 doi:10.1186/s13071-014-0549-8
- 671 65. Ribeiro JMC, Arcà B, Lombardo F, Calvo E, Phan VM, Chandra PK, et al. An  
672 annotated catalogue of salivary gland transcripts in the adult female mosquito, *Aedes*  
673 *aegypti*. *BMC Genom*. 2007;8: 6. doi:10.1186/1471-2164-8-6
- 674 66. Londono-Renteria BL, Shakeri H, Rozo-Lopez P, Conway MJ, Duggan N, Jaber-  
675 Douraki M, et al. Serosurvey of human antibodies recognizing *Aedes aegypti* D7  
676 salivary proteins in Colombia. *Front Public Health*. 2018;6: 11.  
677 doi:10.3389/fpubh.2018.00111
- 678 67. World Health Organization & Onchocerciasis Control Programme in West Africa.  
679 Socio-demographic study in the Pru Basin. Ouagadougou 11–15 March 2002.  
680 Available: <https://apps.who.int/iris/handle/10665/311605> (accessed 11 December  
681 2021).
- 682 68. Kim R, van Moorsel T, Kapstein EB. The National and Regional Socio-Economic  
683 Impact of Newmont Ghana’s Ahafo Mine. Steward Redqueen Rep. 2013. Available:  
684 [https://s24.q4cdn.com/382246808/files/doc\\_downloads/operations\\_projects/africa/quic](https://s24.q4cdn.com/382246808/files/doc_downloads/operations_projects/africa/quic)  
685 [k\\_links/Socio-economic-impact-of-Ahafo-Operations.pdf](https://s24.q4cdn.com/382246808/files/doc_downloads/operations_projects/africa/quic_k_links/Socio-economic-impact-of-Ahafo-Operations.pdf) (accessed 11 December  
686 2021).
- 687 69. Klein SL, Flanagan KL. Sex differences in immune responses. *Nat Rev Immunol*.  
688 2016;16: 626–638. doi:10.1038/nri.2016.90
- 689 70. White MT, Griffin JT, Akpogheneta O, Conway DJ, Koram KA, Riley EM, et al.  
690 Dynamics of the antibody response to *Plasmodium falciparum* infection in African  
691 children. *J Infect Dis*. 2014;210: 1115–1122. doi:10.1093/infdis/jiu219
- 692 71. Yman V, White MT, Rono J, Arcà B, Osier FH, Troye-Blomberg M, et al. Antibody  
693 acquisition models: A new tool for serological surveillance of malaria transmission  
694 intensity. *Sci Rep*. 2016;6: 1–10. doi:10.1038/srep19472
- 695 72. Remoue F, Alix E, Cornélie S, Sokhna C, Cissé B, Doucoure S, et al. IgE and IgG4  
696 antibody responses to *Aedes* saliva in African children. *Acta Trop*. 2007;104: 108–115.  
697 doi:10.1016/j.actatropica.2007.07.011
- 698 73. Varga EM, Kausar F, Aberer W, Zach M, Eber E, Durham SR, et al. Tolerant  
699 beekeepers display venom-specific functional IgG4 antibodies in the absence of  
700 specific IgE. *J Allergy Clin Immunol*. 2013;131: 1419–1421.  
701 doi:10.1016/j.jaci.2012.08.037
- 702 74. García-Robaina JC, De La Torre-Morín F, Vazquez-Moncholi C, Fierro J, Bonnet-  
703 Moreno C. The natural history of *Apis*-specific IgG and IgG4 in beekeepers. *Clin Exp*  
704 *Allergy*. 1997;27: 418–423. doi:10.1111/j.1365-2222.1997.tb00727.x
- 705 75. World Health Organization. Department of Control of Neglected Tropical Diseases.

706 Report of the Third Meeting of the WHO Onchocerciasis Technical Advisory  
707 Subgroup Geneva, Switzerland, 26–28 February 2019 (Editor: Cantey P). Available:  
708 <https://www.who.int/publications/i/item/9789240006638> (accessed 11 December  
709 2021).